Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pacira Biosciences

Decoding 6 Analyst Evaluations For Pacira BioSciences

Across the recent three months, 6 analysts have shared their insights on Pacira BioSciences (NASDAQ:PCRX), expressing a variety of opinions spanning from bullish to bearish.

3 Pharma Gems Poised for Breakthroughs

3 Pharma Gems Poised for Breakthroughs

The pharmaceutical industry is rapidly expanding, fueled by continued R&D efforts leading to the discovery of new drugs and therapies, biotechnology innovations, and growing medical needs. Thus, let’s take a look at pharma gems Pacira BioSciences (PCRX), Calliditas Therapeutics (CALT), and Astellas Pharma (ALPMY) poised for breakthroughs. Read more….

3 Pharma Stocks for January 2024 Profits

3 Pharma Stocks for January 2024 Profits

The pharmaceutical industry is thriving, fueled by steady demand for drugs, cost-efficient alternative discoveries, and rapid technological innovations. Hence, fundamentally strong pharma stocks Novo Nordisk (NVO), Eton Pharmaceuticals (ETON), and Pacira BioSciences (PCRX) might be profitable buys now. Read on….

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Third Circuit Rejects Pacira Biosciences' Trade Libel Claim Over Article in Leading Medical Journal About EXPAREL

From Friday's Third Circuit decision in Pacira Biosciences, Inc. v. American Society of Anesthesiologists, Inc., written by Judge Patty Shwartz, joined by Judges Stephanos Bibas and Thomas Ambro: Pacira BioSciences, Inc. … sued the American Society of Anesthesiologists, Inc. …, the editor-in-chief of its medical journal, and the authors of…

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24 hours, at $53.47 per share.

Pacira BioSciences's Return on Invested Capital Overview

Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters.

inkl

Read news from The Economist, FT, and more,
with one subscription

Pacira BioSciences: Q1 Earnings Insights

Pacira BioSciences: Q1 Earnings Insights

Pacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Pacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know

Pacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know

Pacira BioSciences (NASDAQ:PCRX) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

Court Rejects Pacira Biosciences' Trade Libel Claim Over Article in Leading Medical Journal About EXPAREL

"The peer-review process—not a courtroom—... provides the best mechanism for resolving scientific uncertainties."

People

Kritika SarmahHer

Stephanos Bibas

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Medical Pharmaceuticals

US Food and Drug Administration

Novo Nordisk AS

Astellas Pharma Inc

Bicycle rapeutics

Ionis Pharmaceuticals

Pacira Biosciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play